153 related articles for article (PubMed ID: 15720188)
21. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.
Chen L; Agrawal S; Zhou W; Zhang R; Chen J
Proc Natl Acad Sci U S A; 1998 Jan; 95(1):195-200. PubMed ID: 9419352
[TBL] [Abstract][Full Text] [Related]
22. Murine double minute 2 as a therapeutic target for radiation sensitization of lung cancer.
Cao C; Shinohara ET; Niermann KJ; Donnelly EF; Chen X; Hallahan DE; Lu B
Mol Cancer Ther; 2005 Aug; 4(8):1137-45. PubMed ID: 16093429
[TBL] [Abstract][Full Text] [Related]
23. Molecular imaging of MDM2 messenger RNA with 99mTc-labeled antisense oligonucleotides in experimental human breast cancer xenografts.
Fu P; Shen B; Zhao C; Tian G
J Nucl Med; 2010 Nov; 51(11):1805-12. PubMed ID: 20956468
[TBL] [Abstract][Full Text] [Related]
24. MDM2 splice variants and their therapeutic implications.
Harris LC
Curr Cancer Drug Targets; 2005 Feb; 5(1):21-6. PubMed ID: 15720186
[TBL] [Abstract][Full Text] [Related]
25. Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene.
Meye A; Würl P; Bache M; Bartel F; Grünbaum U; Mansa-ard J; Schmidt H; Taubert H
Cancer Lett; 2000 Feb; 149(1-2):181-8. PubMed ID: 10737722
[TBL] [Abstract][Full Text] [Related]
26. Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination.
Mu Z; Hachem P; Agrawal S; Pollack A
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):336-43. PubMed ID: 14751501
[TBL] [Abstract][Full Text] [Related]
27. The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells.
Traidej M; Chen L; Yu D; Agrawal S; Chen J
Antisense Nucleic Acid Drug Dev; 2000 Feb; 10(1):17-27. PubMed ID: 10726657
[TBL] [Abstract][Full Text] [Related]
28. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression.
Chen L; Lu W; Agrawal S; Zhou W; Zhang R; Chen J
Mol Med; 1999 Jan; 5(1):21-34. PubMed ID: 10072445
[TBL] [Abstract][Full Text] [Related]
29. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.
Rayburn E; Zhang R; He J; Wang H
Curr Cancer Drug Targets; 2005 Feb; 5(1):27-41. PubMed ID: 15720187
[TBL] [Abstract][Full Text] [Related]
30. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
31. Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo.
Stoyanova R; Hachem P; Hensley H; Khor LY; Mu Z; Hammond ME; Agrawal S; Pollack A
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1151-60. PubMed ID: 17637390
[TBL] [Abstract][Full Text] [Related]
32. MDM2 is a central node in the p53 pathway: 12 years and counting.
Bond GL; Hu W; Levine AJ
Curr Cancer Drug Targets; 2005 Feb; 5(1):3-8. PubMed ID: 15720184
[TBL] [Abstract][Full Text] [Related]
33. Transfection with mdm2-antisense or wtp53 results in radiosensitization and an increased apoptosis of a soft tissue sarcoma cell line.
Grünbaum U; Meye A; Bache M; Bartel F; Würl P; Schmidt H; Dunst J; Taubert H
Anticancer Res; 2001; 21(3B):2065-71. PubMed ID: 11497299
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1.
Sato N; Mizumoto K; Maehara N; Kusumoto M; Nishio S; Urashima T; Ogawa T; Tanaka M
Anticancer Res; 2000; 20(2A):837-42. PubMed ID: 10810363
[TBL] [Abstract][Full Text] [Related]
35. The effect of Tc-99m-labeled MDM2 antisense oligonucleotide on gene expression in human breast cancer MCF-7 cells.
Zhao C; Fu P; Sheng Y; Li Z
J Exp Ther Oncol; 2007; 6(4):297-303. PubMed ID: 18038763
[TBL] [Abstract][Full Text] [Related]
36. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis.
Kondo S; Barnett GH; Hara H; Morimura T; Takeuchi J
Oncogene; 1995 May; 10(10):2001-6. PubMed ID: 7761100
[TBL] [Abstract][Full Text] [Related]
37. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
[TBL] [Abstract][Full Text] [Related]
38. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol.
Saji S; Nakashima S; Hayashi S; Toi M; Saji S; Nozawa Y
Jpn J Cancer Res; 1999 Feb; 90(2):210-8. PubMed ID: 10189892
[TBL] [Abstract][Full Text] [Related]
40. Antisense therapy: recent advances and relevance to prostate cancer.
Benimetskaya L; Stein CA
Clin Prostate Cancer; 2002 Jun; 1(1):20-30. PubMed ID: 15046709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
